Highlights eFFECTOR Therapeutics, Inc. Deutsche Boerse AG

Equities

LWK1

US28202V1089

Real-time Estimate Tradegate Other stock markets 05:30:21 2024-07-01 EDT			5-day change	1st Jan Change
0.247 ^EUR	-77.02%		-8.12%	-88.97%

06-24	Sector Update: Health Care Stocks Rise in Late Afternoon Trading	MT
06-24	Top Midday Decliners	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Sector Update: Health Care Stocks Rise in Late Afternoon Trading	06-24	MT
Sector Update: Health Care Stocks Advance Monday Afternoon	06-24	MT
EFFECTOR Therapeutics to Shut Down Operations, Seeking Strategic Alternatives	06-24	MT
EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer	05-20	CI
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Health Care Down on Retreat From Risk -- Health Care Roundup	04-04	DJ
Top Midday Decliners	04-04	MT
EFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer	04-04	CI
Top Premarket Decliners	03-26	MT
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-25	CI
EFFECTOR Therapeutics, Inc. Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients	12-08	CI
EFFECTOR Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of Er+/Her2- Advanced Metastatic Breast Cancer	11-28	CI
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Effector Therapeutics, Inc. Announces Initiation of Dosing in an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Relapsed/Refractory Acute Myeloid Leukemia	23-10-24	CI
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Debt Talks Progress Lift Exchange-Traded Funds, Equity Futures Pre-Bell Friday	23-05-26	MT
EFFECTOR Reports 'Positive' Data Updates in Mid-Stage Breast Cancer Trial; Shares Soar After-Hours	23-05-25	MT
EFFECTOR Therapeutics, Inc. Announces Positive Interim Data Updates from Phase 2 Expansion Cohort Evaluating Zotatifin Combined with Fulfvestrant and Abemaciclib	23-05-25	CI
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
EFFECTOR Therapeutics, Inc. to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer	23-04-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights eFFECTOR Therapeutics, Inc. Deutsche Boerse AG

Equities

LWK1

US28202V1089

Highlights

Filters